ZNF428 Inhibitors
Chemical inhibitors of ZNF428 function by targeting various signaling pathways that are essential for its activity. Wortmannin and LY294002 are both inhibitors of phosphatidylinositol 3-kinase (PI3K), an enzyme involved in the PI3K/AKT/mTOR signaling cascade, which is a common regulatory pathway for many proteins. By inhibiting PI3K, these chemicals impede the pathway's ability to activate downstream targets that could include ZNF428. Similarly, Triciribine directly targets AKT, another key component of the same pathway, offering a more downstream blockade that can also affect the function of ZNF428.
Additional chemicals operate through different mechanisms but still converge on the possibility of altering ZNF428 activity. U0126 and PD98059 both act as inhibitors of MEK1/2, key enzymes in the MAPK/ERK pathway, which is another crucial signaling route that can affect various proteins. By preventing the activation of MEK, these inhibitors potentially suppress the ERK pathway's influence on ZNF428. SB203580, on the other hand, targets p38 MAP kinase, and SP600125 inhibits c-Jun N-terminal kinase (JNK), both of which are part of the MAPK family. By inhibiting these kinases, the chemicals can reduce the function of ZNF428 if it is regulated by either p38 or JNK MAPK pathways. In the realm of tyrosine kinase signaling, PP2, Dasatinib, and PD173955 focus on inhibiting the Src family of tyrosine kinases. Src kinases are implicated in multiple cellular processes, and their inhibition by these chemicals can decrease ZNF428 activity if Src signaling is a part of the regulatory mechanism. Palbociclib, which inhibits CDK4/6, is known to halt cell cycle progression, and this interruption could affect ZNF428 if its function is related to the cell cycle. Lastly, Rapamycin, an mTOR inhibitor, can suppress ZNF428 function by disrupting the mTOR signaling pathway, which might be involved in the regulation or activity of ZNF428.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor. Since ZNF428 activity is potentially regulated via PI3K signaling pathways, inhibition of PI3K by Wortmannin could lead to a downstream reduction in ZNF428 protein activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that operates similarly to Wortmannin. By inhibiting PI3K, LY294002 could lead to the suppression of any PI3K-dependent regulatory mechanisms that control ZNF428 protein activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 selectively inhibits MEK1/2, which are upstream of ERK in the MAPK pathway. Given that ZNF428 protein function may be influenced by MAPK signaling, U0126 inhibition of MEK could result in decreased ZNF428 protein function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that prevents the activation of ERK1/2. By impeding this pathway, PD98059 would inhibit the function of ZNF428 if the protein's activity is ERK-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, and by inhibiting this kinase, it could suppress the function of ZNF428 protein if p38 MAPK is involved in the regulatory pathway of ZNF428. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK by SP600125 could lead to the inhibition of ZNF428 protein function if JNK signaling influences ZNF428 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinase signaling can regulate various proteins, so inhibition of Src by PP2 could lead to a reduction in ZNF428 protein function if Src signaling is involved in its regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases. By inhibiting Src kinases, Dasatinib could suppress ZNF428 protein function if Src signaling is part of ZNF428's regulatory mechanisms. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor and could inhibit ZNF428 protein function by halting the cell cycle progression at the G1 phase, which could be necessary for the proper function or regulation of ZNF428. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and could inhibit ZNF428 protein function by disrupting the mTOR signaling pathway, which may play a role in the regulation or activity of ZNF428. | ||||||